Market Overview

GW Pharmaceuticals Shares Jump Following Price Target Raise

Share:
Related GWPH
Pot Stock Watch: Why Is Zynerba Viewed As A Sympathy Play With GW Pharma?
Exclusive: GW Pharmaceuticals Talks Epidiolex, Raising Capital & Growing Its Sales Force
Latest GW Pharmaceuticals Cannabinoid Drug Test Results Boost Stock Price Again (Seeking Alpha)

In a note released Monday morning, Piper Jaffray made a big raise to the price target of GW Pharmaceuticals (NASDAQ: GWPH) from $97 to $147, citing the potential of GW's Epidiolex to treat epilepsy.

The analysts at Piper Jaffray say that the unique safety/CNS profile make the drug an attractive way to treat epilepsy.

Additionally, the analysts noted that they do not believe INSYS Therapeutics will be able to compete on price.

Following the note, shares of GW Pharmaceuticals are up over six percent in the pre-market.

Latest Ratings for GWPH

DateFirmActionFromTo
Sep 2016Morgan StanleyMaintainsOverweight
Sep 2016Cantor FitzgeraldMaintainsBuy
Jun 2016Janney CapitalInitiates Coverage onSell

View More Analyst Ratings for GWPH
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color News Price Target Analyst Ratings

 

Related Articles (GWPH)

View Comments and Join the Discussion!